MAPK1 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, targeting ERK1 and ERK2 by inhibiting the expression of GRB2, which is a potent activator of ERK1 and ERK2, has been shown to be effective in the treatment of CML patients with refractory or relapsed disease34,35.